Disease Landscape and Forecast Insights

The Hodgkin’s Lymphoma therapy market—currently dominated by multidrug chemotherapy regimens—will experience significant growth over the 2015-2025 forecast. This growth will be fueled by the…

Type 2 diabetes (T2D) is a chronic metabolic disease affecting more than 28 million people in the five major European pharmaceutical markets (France, Germany, Italy, Spain, United Kingdom; EU5). At…

Type 2 diabetes and obesity are chronic diseases that affect millions of Americans and represent a costly expense for the nation’s healthcare payers. In the effort to manage quality and costs…

Last Updated 29 December 2015 Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The recent…

Last Updated 16 December 2015 Parkinson’s disease (PD) is one of the most common chronic neurodegenerative diseases in the elderly; its prevalence is expected to grow 2% annually in the major…

The prevalence of difficult-to-treat infections is increasing worldwide, despite regional variations in the etiological pathogens. This report provides an extensive overview of the use of…

Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important Gram-positive pathogen in both the hospital and outpatient settings. The recent FDA approvals of oritavancin (The…

Patients with osteoporosis and osteopenia are at increased risk of suffering fractures. These fractures place a considerable burden on public health systems, and significant unmet need remains in…

LaunchTrends: Keytruda Wave 3 (US) is the third in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the malignant melanoma drug…

Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common reason for liver transplantation in Europe. The recent market…

The malignant melanoma treatment landscape is dynamic and continues to undergo significant changes. Since 2011, three immune checkpoint inhibitors and four BRAF- or MEK-targeted agents have gained…

Market Access Opportunities for Novel Therapies Targeting Multi-Drug-Resistant Pathogens Hospital-treated Gram-negative infections (GNIs) are becoming increasingly difficult to treat given rising…